Myovant Sciences Ltd Stock News

Myovant Sciences (MYOV) delivered earnings and revenue surprises of -219.05% and -32.89%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Shares of Myovant Sciences (NYSE:MYOV) rose 1.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 81.08% year over year to ($0.67), which mis

The European Commission (EC) has approved Myovant Sciences Ltd's (NYSE: MYOV) Ryeqo (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for the treatment of moderate to severe sym

BASEL, Switzerland, July 20, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the European Commission (E

Eli Lilly (LLY), Pfizer (PFE) and Bayer (BAYRY) are three large drug sector companies worth buying and holding for the next few months and beyond.

This could be a breakthrough year for these three biotech stocks, resulting in massive gains for their stockholders similar to Biogen. The post 3 Biotech Stocks Ready for Big Breakthroughs Like Biogen

A lesser-known British biotech is among eight pharma companies the publication Kiplinger encouraged readers to monitor for important key clinical trial results or regulatory approvals.

Myovant recently cleared another regulatory binary for relugolix as a treatment for uterine fibroids. On top of the clearance for advanced prostate cancer, Relugolix is now approved for two indication

BASEL, Switzerland, June 01, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to

The FDA has approved Myovant Sciences Ltd (NYSE: MYOV) and Pfizer Inc's (NYSE: PFE) relugolix combined with estradiol and norethindrone acetate for heavy menstrual bleeding linked to uterine fibr

LONDON and NEW YORK, May 26, 2021 /PRNewswire/ -- Sumitovant Biopharma, Inc. today announced that its portfolio of four wholly owned subsidiary companies (Urovant, Enzyvant, Altavant and Spirovan

European Medicines Agency's advisory committee issued a positive opinion recommending the approval of Myovant Sciences Ltd's (NYSE: MYOV) Ryeqo (relugolix, estradiol, and norethindrone acetate) fo

BASEL, Switzerland, May 21, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopt

Myovant Sciences Ltd (NYSE: MYOV) has received a partial clinical hold on its SERENE study (MVT-601-050) from the FDA. The Phase 3 study was evaluating relugolix combination tablets for the prevent

Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q4 2020 Results - Earnings Call Transcript